8-K: Celcuity Secures $180 Million Debt Financing and Announces Phase 3 Trial for Breast Cancer Drug

Celcuity Inc. has secured up to $180 million in debt financing to support the initiation of a Phase 3 clinical trial for its drug gedatolisib in treating advanced breast cancer.

Summary

• Celcuity Inc. has amended its existing debt facility, securing up to $180 million in term loans from Innovatus Capital Partners and Oxford Finance.
• The company received an initial $61.7 million, bringing their total debt to $100 million.
• Additional tranches of $30 million and $50 million are available upon achieving certain clinical trial and regulatory milestones.
• The debt facility includes a 36-month interest-only period, extendable to 48 months under certain conditions, with loans maturing in five years.
• Celcuity plans to initiate a Phase 3 clinical trial, VIKTORIA-2, for gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as a first-line treatment for HR+/HER2advanced breast cancer.
• The trial will enroll approximately 638 subjects across up to 200 clinical sites in North America, Europe, Latin America, and Asia.
• The first patient is expected to be enrolled in the second quarter of 2025.
• The primary endpoints of the trial are progression-free survival (PFS), assessed separately in PI3KCA wild type and mutant subjects.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a significant financing and a new Phase 3 trial. However, there are inherent risks associated with clinical trials and debt financing, which temper the overall sentiment.

Positives

• The $180 million debt financing provides substantial capital to support the Phase 3 clinical trial and general business operations.
• The extended interest-only period of up to 48 months provides financial flexibility.
• The Phase 3 trial design was reviewed and discussed with the FDA, indicating regulatory alignment.
• The trial allows investigators to choose between ribociclib or palbociclib, potentially increasing enrollment and applicability.
• The trial design includes separate randomization based on PIK3CA mutation status, allowing for more targeted analysis.

Negatives

• The company is taking on a significant amount of debt, which could increase financial risk.
• The clinical trial is complex and requires a large number of participants, which could lead to delays or challenges in enrollment.
• The combination of gedatolisib with ribociclib has not been clinically tested, requiring a safety run-in phase.

Risks

• The success of the Phase 3 trial is not guaranteed, and the drug may not achieve its primary endpoints.
• Regulatory approvals are not guaranteed, and the drug may not be approved for commercialization.
• The company's ability to repay the debt is dependent on the success of the clinical trial and commercialization of the drug.
• There are risks associated with the clinical trial, including unforeseen delays, challenges in enrollment, and adverse events.
• The company faces competition from other therapies and may not achieve market acceptance.

Future Outlook

Celcuity plans to initiate the Phase 3 VIKTORIA-2 clinical trial in the second quarter of 2025 and will continue to pursue the development of gedatolisib for multiple solid tumor indications. The company will also continue to draw down on the debt facility as clinical and regulatory milestones are achieved.

Management Comments

• Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity, stated, 'There is an urgent need for better first-line treatment options for HR+/HER2advanced breast cancer patients whose disease progressed while on or within 12 months of completing adjuvant endocrine for early breast cancer.'
• Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity, stated, 'We are very encouraged by the preliminary clinical data for gedatolisib as first-line treatment in patients with advanced breast cancer.'
• Brian Sullivan, CEO and co-founder of Celcuity, said, 'We are excited to have secured the additional capital so we could accelerate initiation of our second Phase 3 study.'
• Brian Sullivan, CEO and co-founder of Celcuity, said, 'Allowing investigators to choose between ribociclib or palbociclib as the CDK4/6 inhibitor for their patients, and separately randomizing patients according to their PIK3CA status, are important elements of the trial design. We are pleased that the FDA concurred with our approach.'

Industry Context

This announcement is significant in the context of the ongoing need for improved treatments for advanced breast cancer, particularly for patients who have developed resistance to endocrine therapy. The trial design, which allows for investigator choice of CDK4/6 inhibitors and stratification by PIK3CA mutation status, reflects a growing trend towards personalized medicine in oncology. The financing also highlights the continued interest of investors in the biotechnology sector, particularly in companies developing novel cancer therapies.

Comparison to Industry Standards

• The median progression-free survival (PFS) of 48.6 months and overall response rate (ORR) of 79% observed in Celcuity's Phase 1b trial are promising compared to standard first-line treatments for HR+/HER2advanced breast cancer.
• For example, the PALOMA-2 trial, which evaluated palbociclib plus letrozole, reported a median PFS of 27.6 months, while the MONALEESA-2 trial, which evaluated ribociclib plus letrozole, reported a median PFS of 25.3 months.
• The VIKTORIA-2 trial's design, which includes a safety run-in for the gedatolisib and ribociclib combination, is consistent with industry best practices for evaluating novel drug combinations.
• The trial's global scope, with up to 200 clinical sites, is comparable to other large-scale Phase 3 oncology trials.
• The use of blinded independent central review for assessing PFS is a standard practice in oncology clinical trials to minimize bias.

Stakeholder Impact

• Shareholders: The financing and clinical trial announcement are likely to be viewed positively, potentially increasing share value.
• Employees: The company's growth and development may lead to job security and opportunities.
• Patients: The clinical trial offers hope for a new treatment option for advanced breast cancer.
• Lenders: The debt financing provides a return on investment, but also carries risk.
• Suppliers: The company's growth may lead to increased business opportunities for suppliers.

Next Steps

• Celcuity will initiate the Phase 3 VIKTORIA-2 clinical trial.
• The company will complete the safety run-in phase for the gedatolisib and ribociclib combination.
• Celcuity will enroll the first patient in the second quarter of 2025.
• The company will continue to draw down on the debt facility as clinical and regulatory milestones are achieved.

Key Dates

Keywords

gedatolisib, breast cancer, clinical trial, Phase 3, debt financing, oncology, PI3K inhibitor, mTOR inhibitor, HR+/HER2-, Innovatus, Oxford Finance, VIKTORIA-2, CDK4/6 inhibitor, fulvestrant